Biotech features clinical-stage trial failures rates that are above 90% and that makes investing in the industry treacherous. If you don't do your homework, you can wind up losing a lot of money. So, with that in mind, I went searching for hot biotech stocks that deserve a closer look and discovered Madrigal Pharmaceuticals (NASDAQ: MDGL) and NuCana Plc (Nasdaq: NCNA).